Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Chart Validation Study Evaluating the Performance of Machine Learning Algorithm (ML) to Predict the Clinical Diagnosis of Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt-CM) and Non-amyloid Heart Failure Among Patients With Heart Failure (HF)

NCT06029452 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06029452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06029452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Chart Validation Study Evaluating the Performance of Machine Learning Algorithm (ML) to Predict the Clinical Diagnosis of Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt-CM) and Non-amyloid Heart Failure Among Patients With Heart Failure (HF)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
September 1, 2023
Completion date
November 14, 2023
Enrollment
558 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attr-cm